Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes

Leucocyte-Rich and Platelet-Rich Fibrin(L-PRF) for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Long Term Follow-up

“…Two types of treatment approaches are generally available for MRONJ treatment first of which is conservative approach, the other involves a more aggressive approach with tight closure to prevent microbial contamination after necrotic and exposed bone removal in severe cases. In the radical treatment of cases involving mandibular resection, block grants from the iliac crest accompanied with miniplate and screw systems are preferred for reconstruction of the relevant region [3]. AAOMS supports a multidisciplinary approach to patients against the risk of osteonecrosis.…”

Osteonecrosis of the Jaw Related to Oral Bisphosphonate Treatment: A Clinical Case

“…66 Overall, in order to stabilize the symptoms some authors propose a conservative treatment of the lesions, continued long-lasting antibiotic therapy, and discontinuation of bisphosphonates when possible. 49,[51][52] Other authors propose the application of plasma rich in growth factors as an alternative therapy in order to stimulate the angiogenesis and repair of the local bone tissue. [67][68][69] Decisions should be made by a complete multidisciplinary team (oral and maxillofacial surgeon, oncologist, and rheumatologist) on the basis of the current clinical stage according to the AAOMS.…”

“…[67][68][69] Decisions should be made by a complete multidisciplinary team (oral and maxillofacial surgeon, oncologist, and rheumatologist) on the basis of the current clinical stage according to the AAOMS. 51,70 …”

“…They advise conservative or minimally aggressive treatments combined with long-lasting antibiotic therapy. 45,[49][50][51] It is desirable for specialists involved in administration of these therapies to count on studies designed with consensual, globally unified protocols that provide them with useful, validated information.…”

Sunitinib és zoledronsav által indukált állcsont-osteonecrosis

“…Használata a beteg számára kevésbé megterhelő, mivel lebenyképzést nem igényel, kevésbé fájdalmas, kevesebb vérzéssel jár [30]. Amennyiben a beteg általános egészségi állapota miatt ellenjavallt a sebé-szi beavatkozás, a konzervatív terápia akár 70%-os sikerességgel, de sajnos sokszor csak átmenetileg, javíthatja vagy megállíthatja a betegséget [31].…”